(Click here for company profile.) PTC Therapeutics has developed three proprietary technologies to screen for, and identify, small-molecule drug targets within the RNA translation process.

As an array of developers push their Friedreich’s ataxia (FA) drugs along, PTC Therapeutics Inc.’s recent update on its program piqued thirst for the 15-lipoxygenase inhibitor vatiquinone. Warren, N.J ...